Literature DB >> 23082780

Intestinal microbial profiles in extremely preterm infants with and without necrotizing enterocolitis.

Erik Normann1, Annika Fahlén, Lars Engstrand, Helene Engstrand Lilja.   

Abstract

AIM: Necrotizing enterocolitis (NEC) represents one of the gravest complications in premature infants. The suggested role of intestinal microbiota in the development of NEC needs to be elucidated.
METHODS: This prospective single-centre case-control study applied barcoded pyrosequencing to map the bacterial composition of faecal samples from extremely preterm infants. Ten patients were diagnosed with NEC and matched to healthy controls with regard to sex, gestational age and mode of delivery prior to analysis of the samples.
RESULTS: Enterococcus, Bacillales and Enterobacteriaceae dominated the flora. Although not statistically significant, a high relative abundance of Bacillales and Enterobacteriaceae was detected at early time points in patients developing NEC, while healthy controls had a microbiota more dominated by Enterococcus. A low diversity of intestinal microbial flora was found without any differences between NEC patients and controls. In 16 healthy controls, Firmicutes (Enterococcus and Bacillales) dominated the faecal flora during the first weeks after birth and were then succeeded by Enterobacteriaceae.
CONCLUSION: No significant differences in the composition of intestinal microbiota of patients developing NEC were detected; however, some findings need to be scrutinized in subsequent studies. ©2012 The Author(s)/Acta Paediatrica ©2012 Foundation Acta Paediatrica.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23082780     DOI: 10.1111/apa.12059

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  45 in total

Review 1.  Probiotics, Prebiotics, and Synbiotics for the Prevention of Necrotizing Enterocolitis.

Authors:  Kathene C Johnson-Henry; Thomas R Abrahamsson; Richard You Wu; Philip M Sherman
Journal:  Adv Nutr       Date:  2016-09-15       Impact factor: 8.701

Review 2.  The Microbiome and Biomarkers for Necrotizing Enterocolitis: Are We Any Closer to Prediction?

Authors:  Brigida Rusconi; Misty Good; Barbara B Warner
Journal:  J Pediatr       Date:  2017-06-29       Impact factor: 4.406

3.  Microbiota-nourishing Immunity and Its Relevance for Ulcerative Colitis.

Authors:  Mariana X Byndloss; Yael Litvak; Andreas J Bäumler
Journal:  Inflamm Bowel Dis       Date:  2019-04-11       Impact factor: 5.325

4.  Urinary intestinal fatty acid binding protein predicts necrotizing enterocolitis.

Authors:  Katherine E Gregory; Abigail B Winston; Hidemi S Yamamoto; Hassan Y Dawood; Titilayo Fashemi; Raina N Fichorova; Linda J Van Marter
Journal:  J Pediatr       Date:  2014-03-15       Impact factor: 4.406

5.  Dysbiosis in the inflamed intestine: chance favors the prepared microbe.

Authors:  Sebastian E Winter; Andreas J Bäumler
Journal:  Gut Microbes       Date:  2014-01-29

6.  [A review on the characteristics of microbiome and their association with diseases in preterm infants].

Authors:  Qiong Jia; Xiao-Mei Tong
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2020-11

Review 7.  Pathogenesis of neonatal necrotizing enterocolitis.

Authors:  Joanna C Lim; Jamie M Golden; Henri R Ford
Journal:  Pediatr Surg Int       Date:  2015-04-09       Impact factor: 1.827

Review 8.  The germ-organ theory of non-communicable diseases.

Authors:  Mariana X Byndloss; Andreas J Bäumler
Journal:  Nat Rev Microbiol       Date:  2018-01-08       Impact factor: 60.633

Review 9.  The impact of the milk glycobiome on the neonate gut microbiota.

Authors:  Alline R Pacheco; Daniela Barile; Mark A Underwood; David A Mills
Journal:  Annu Rev Anim Biosci       Date:  2014-11-05       Impact factor: 8.923

Review 10.  Why related bacterial species bloom simultaneously in the gut: principles underlying the 'Like will to like' concept.

Authors:  Sebastian E Winter; Andreas J Bäumler
Journal:  Cell Microbiol       Date:  2013-12-16       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.